SCHEMBL3969609

SCHEMBL3969609

NCC1CCC(CNc2nccc(-c3cc4ccccc4s3)n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 11/20 0.50
CHUK O15111 9/20 0.50
IKBKG Q9Y6K9 9/20 0.50
VCP P55072 1/20 0.47
MEN1 O00255 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
PRKCZ Q05513 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
USP30 Q70CQ3 2/20 0.40
CDC7 O00311 2/20 0.40
ROCK2 O75116 1/20 0.40
CCNB2 O95067 1/20 0.40
MAP4K4 O95819 1/20 0.40
CDK1 P06493 1/20 0.40
RET P07949 1/20 0.40
CCNB1 P14635 1/20 0.40
PRKACA P17612 1/20 0.40
CDK2 P24941 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13768223 1.00 IKBKB (0.50) IKBKBCHUKIKBKGVCPMEN1
SCHEMBL3965709 0.80 ACACB (0.51) IKBKBCHUKIKBKGVCPMEN1
SCHEMBL3965706 0.80 ACACB (0.51) IKBKBCHUKIKBKGVCPMEN1
SCHEMBL4093923 0.77 IKBKB (0.48) IKBKBCHUKIKBKGVCPMEN1
SCHEMBL13799539 0.76 IKBKB (0.56) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL3965369 0.76 IKBKB (0.39) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL4896094 0.72 IKBKB (0.50) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL3472229 0.72 IKBKB (0.54) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL4484933 0.72 IKBKB (0.49) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL13633704 0.70 IKBKB (0.48) IKBKBCHUKIKBKGMEN1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG IKBKB 2/4885CHUK 5/4885IKBKG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.